A5059344851- Prostate Cancer Treatment and Research
- Epigenetics and DNA Methylation
- Cancer Immunotherapy and Biomarkers
- Liver Disease Diagnosis and Treatment
- Liver Disease and Transplantation
- Radiopharmaceutical Chemistry and Applications
- Organ Transplantation Techniques and Outcomes
- Psoriasis: Treatment and Pathogenesis
- Cancer-related molecular mechanisms research
- Pancreatic and Hepatic Oncology Research
- PARP inhibition in cancer therapy
- Chronic Lymphocytic Leukemia Research
- Art, Technology, and Culture
- Bioinformatics and Genomic Networks
- Cancer Treatment and Pharmacology
- Renal Transplantation Outcomes and Treatments
- Architecture and Computational Design
- Pancreatitis Pathology and Treatment
- Pharmaceutical studies and practices
- Prostate Cancer Diagnosis and Treatment
- Surface Treatment and Coatings
- Healthcare cost, quality, practices
- Ferroptosis and cancer prognosis
- Autopsy Techniques and Outcomes
- Hedgehog Signaling Pathway Studies
Royal Children's Hospital
2024
Alfred Health
2022
St Vincent's Hospital
2019-2020
The University of Melbourne
2019
Indiana University School of Medicine
2007-2018
Indiana University – Purdue University Indianapolis
2006-2018
Indiana University Health
2012
The University of Texas Health Science Center at San Antonio
2012
Indiana University
2012
Richard L. Roudebush VA Medical Center
2012
Preclinical studies have shown that hypomethylating agents reverse platinum resistance in ovarian cancer. In this phase II clinical trial, based upon the results of our I dose defining study, we tested and biologic activity low-dose decitabine administered before carboplatin platinum-resistant cancer patients. Among 17 patients with heavily pretreated cancer, regimen induced a 35% objective response rate (RR) progression-free survival (PFS) 10.2 months, nine (53%) free progression at 6...
Purpose This multinational, double-blind, randomized, placebo-controlled, phase III trial assessed the efficacy and tolerability of oral platinum analog satraplatin in patients with metastatic castrate-refractory prostate cancer (CRPC) experiencing progression after one prior chemotherapy regimen. Patients Methods Nine hundred fifty were randomly assigned (2:1) to receive (n = 635) 80 mg/m 2 on days 1 5 a 35-day cycle prednisone mg twice daily or placebo 315) daily. Primary end points...
Orthotopic liver transplantation (OLT) is the only definitive treatment for irreversible acute failure and chronic disease. In immediate postoperative period after OLT, patients are closely monitored with Doppler ultrasonography (US) to detect treatable vascular complications ensure graft survival. The first US examination performed fairly early on day, before surgical wound closure has been performed. images, obtained when effects of surgery very recent, often reveal an array findings that...
Background and objectiveAbiraterone acetate (abiraterone) plus prednisone is approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Our aim was to evaluate efficacy safety pembrolizumab abiraterone in mCRPC.MethodsIn cohort D phase 1b/2 KEYNOTE-365 study (NCT02861573), patients were chemotherapy-naïve, had disease progression ≤6 mo before screening, either not received prior next-generation hormonal agents mCRPC or enzalutamide became intolerant enzalutamide....
You have accessJournal of UrologyProstate Cancer: Advanced (including Drug Therapy) II (PD16)1 Apr 2020PD16-12 PEMBROLIZUMAB PLUS ENZALUTAMIDE IN ABIRATERONE-PRETREATED PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: UPDATED RESULTS FROM KEYNOTE-365 COHORT C Evan Y. Yu*, Peter Fong, Josep M. Piulats, Leonard Appleman, Henry Conter, Susan Feyerabend, Neal Shore, Gwenaelle Gravis, Brigitte Laguerre, Howard Gurney, Margitta Retz, Emanuela Romano, Loic Mourey, Johann S. de Bono,...
<h3>Background</h3> Treatment with abiraterone acetate + prednisone can improve outcomes in mCRPC patients or without prior chemotherapy. Cohort D of phase 1b/2 study KEYNOTE-365 (NCT02861573) evaluated safety and efficacy PD-1 inhibitor pembrolizumab who had not received chemotherapy for mCRPC. <h3>Methods</h3> Patients were enrolled second-generation hormonal manipulation failed/were intolerant to enzalutamide mCRPC; progressive disease ≤6 months before screening; ECOG PS 0/1. 200 mg IV...
2529 Background: Synergism between IGF and mTOR inhibitors has been documented preclinically. We conducted a phase I study to determine the safety, recommended II dose (RP2D), pharmacokinetics (PK), pharmacodynamics (PD), antitumor efficacy of E with G. Methods: Eligible pts had good organ function, ECOG PS 0-1. The standard “3+3” design, using 5 or 10 mg orally daily (QD), G 12 mg/kg IV every 2 wks (Q2W) in 28 day cycles (C); an expansion cohort was added at MTD for further analysis. given...
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by authors. Any queries (other than missing content) should be directed to corresponding author article.
much worried by a slight attack of bronchitis, which caused so pain when the abdomen was shaken coughing.On Oct. 2nd Mr. Wells saw her with me.She then
Background Fine needle aspiration (FNA) diagnoses are usually confirmed via surgical pathology or evaluation of clinical outcomes. However, such confirmation may not occur for patients who die shortly after FNA, and autopsy be a useful quality assessment tool in these cases. Also, there is little data investigating the relationship between FNA mortality. We sought to demonstrate as assess contribution mortality soon procedure. Methods A search our database was performed from 1992 2016 were...
At St. Luke's Hospital (New York) our interest in preoperative irradiation followed by radical hysterectomy and node dissection for cervical carcinoma has been stimulated the realization that optimal results have probably attained either modality alone, as exemplified reports from Radiumhemmet on one hand proponents of surgery other. We feel both sides an unhealthy competitive philosophy prevails, which may blinded each to advantages inherent other's method. The value postoperative cervix...
<h3>Background</h3> Previous data from cohort C of phase 1b/2 study KEYNOTE-365 (NCT02861573) showed that PD-1 inhibitor pembrolizumab + enzalutamide was well tolerated and antitumor activity in patients with abiraterone acetate–pretreated mCRPC. Updated after a minimum 22 months follow-up are presented. <h3>Methods</h3> Patients the prechemotherapy mCRPC state who were intolerant to ≥4 weeks' treatment acetate or for whom this failed, had progressive disease ≤6 before screening, ECOG PS 0-2...
5148 Background: First-line chemotherapy trials have reported that pain predicts OS in CRPC. We report relationships between and baseline –a major component of CRPC patient outcomes (PRO) –and at progression, for docetaxel pre-treated patients a second-line trial Methods: Docetaxel pts (N = 488) were analyzed from the multi-national, randomized, double-blind SPARC trial, comparing satraplatin + prednisone vs placebo 950 metastatic pts. Daily intensity narcotic analgesic use recorded as PRO...
Background: AB122 is a fully human monoclonal antibody targeting PD-1. It binds tightly to different PD-1 epitope than other currently approved antibodies in this class. Here we report preliminary data from an ongoing, open-label, dose-escalation (3 + 3 design) study evaluating the safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and antitumor activity of monotherapy patients (pts) with select advanced solid tumors. Methods: Eligible pts had pathologically confirmed...
Objectives Beginning in 2001, the captive insurer of Harvard affiliated teaching hospitals (CRICO/RMF), created premium incentives for anesthesiologists and OB/GYN physicians to participate simulation-based CRM/teamwork training. In 2013, CRICO began offering a rebate surgeons high-risk specialties who participated simulation activity involving team including other clinicians1. The courses are conducted at programs within insured by Center Medical Simulation (CMS). To implement program...